Proteomics in Health and Disease by Wright Jr, George L. & Semmes, O. John
© 2003 Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology • 2003:4 (2003) 215–216 • PII. S1110724303002997 • http://jbb.hindawi.com
EDITORIAL
Proteomics in Health and Disease
George L. Wright Jr∗ and O. John Semmes†
Department of Microbiology and Molecular Cell Biology, Virginia Prostate Center,
Eastern Virginia Medical School, Norfolk, VA 23501, USA
One of the major goals of the postgenomic era is un-
derstanding the structures, interactions, and functions of
allcellproteins.Thisbecomesadauntingtaskconsidering
the estimation that there are between 100000 and 200000
individual proteins resulting from alternative splicing of
the 30000 genes encoded by the human genome. Since
the cellular proteome is a dynamic proﬁle, subject to
change in response to various signals through posttrans-
lational modiﬁcation, translocation, and protein-protein
and protein-nucleic acid interactions, the task becomes
even more complex looming to a million or more mod-
iﬁcation events. Proteomics encompasses the study of ex-
pressed proteins, including identiﬁcation and elucidation
of the structure-function interrelationships which deﬁne
healthy and disease conditions. Information at the level
of the proteome is critical to understanding the function
of cellular phenotype and its role in health and disease.
Since posttranslational events and, indeed, an accurate
assessment of protein expression levels cannot always be
predicted by mRNA analysis, proteomics, used in con-
cert with genomics, can provide a holistic understanding
of the biology underlying the disease process. The chal-
lengeindecipheringtheproteomeisthedevelopmentand
integration of analytical instrumentation combined with
bioinformatics that provide rapid, high-throughput, sen-
sitive, and reproducible tools.
This issue of the Journal of Biomedicine and Biotech-
nology presents the ﬁrst of a two-part series consisting
of ten papers that describe both technical and bioinfor-
matic advances to deﬁne the cell proteome towards a bet-
ter understanding of health and disease. The current is-
sue consists of the ﬁrst ﬁve articles beginning with pa-
pers by Bensmail and Haoudi, and Pruess and Apweiler
that describe bioinformatics approaches for deﬁning the
cancer cell proteome and for in silico proteomic analy-
ses. Because of the high dimensionality of the data gen-
erated by proteomic methodologies, such as protein mi-
croarrays and mass spectral analyses, more eﬃcient and
accurate bioinformatics tools are required to mine and
analyze the data. Major advances in mass spectrometry
have resulted in rapid, high-throughput technologies for
protein biomarker discovery, protein identiﬁcation, dis-
easeanalyses,andidentiﬁcationofposttranslationalmod-
iﬁcations. One advance, SELDI ProteinChip mass spec-
trometry, is the subject of the next two papers that de-
scribeitsuseforbiomarkerdiscoveryanditspotentialasa
platform for development of multimarker clinical assays.
The ﬁrst paper by Reddy and Dalmasso presents a review
describingtheuseofSELDIforbiomarkerdiscovery,drug
discovery, protein identiﬁcation, and for development of
multiplex clinical assays, citing examples for cancer, neu-
rological disorders, and infectious diseases. Feng and as-
sociates then describe an automated peak identiﬁcation
and calibration procedure for more precise mass analyses
when attempting to diﬀerentiate disease from nondisease
protein patterns. The last paper of this issue by Qoron-
ﬂeh and associates describes a method for the isolation of
membrane proteins for proteomic analysis.
The next issue (volume 2003, issue 5) presents the re-
maining ﬁve papers. This issue begins with a review by Xu
and Lam on protein and chemical microarray approaches
beingutilizedforproteomicstudies.ThenFlowerandcol-
leagues describe bioinformatics approaches for deﬁning
the immunome for discovery of novel vaccines. This is
followed by a paper by Qoronﬂeh and colleagues who
describe improved methods for detecting protein: pro-
tein interactions. Piccoli’s research team then report a
method for optimizing the rolling circle application tech-
nology for generating a sensitive high-throughput multi-
plex protein microarray for analysis of protein expression
and molecular diagnosis. The ﬁnal paper in this issue is
by Vlahou and associates who describe the use of SELDI
protein proﬁling coupled with a commercial decision tree
learning algorithm for biomarker discovery and diagnosis
of ovarian cancer.
The content of this special issue, although broad and
addressing several key issues in proteomics research, still
leaves many issues to be covered, especially functional
and structural proteomics, in this fast evolving ﬁeld of
research. We anticipate addressing other new discoveries
and applications in the proteomics ﬁeld in future issues of
the Journal of Biomedicine and Biotechnology.
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